FDA Announces Voluntary Recall of Drugs Containing Valsartan
July 23, 2018
On Friday, July 13th, FDA announced the voluntary recall of several drugs containing the active ingredient valsartan. Valsartan is often used to treat serious medical conditions such as high blood pressure and heart failure. However, in early July, the European Medicines Agency (EMA) recalled several drugs containing valsartan due to impurity concerns. N-nitrosodimethylamine (NDMA), a probable human carcinogen, was found in the recalled products.
According to a recent statement from the FDA, “the presence of NDMA was unexpected and is thought to be related to changes in the way the active substance was manufactured. The FDA’s review is ongoing and has included investigating the levels of NDMA in the recalled products, assessing the possible effect on patients who have been taking them and what measures can be taken to reduce or eliminate the impurity from future batches produced by the company.”
FDA has recalled five valsartan-containing medications:
However, it is important to note that not all products containing valsartan have been recalled. At this time, only valsartan supplied by Zhejiang Huahai Pharmaceuticals is being recalled. An updated list of FDA drug recalls can be found here.
In the FDA’s July 13thnews release includes information for patients and healthcare providers who use or provide valsartan-containing medication. According to the statement:
Patients should contact a healthcare professional to discuss an alternative treatment plan, however, medication should continue to be taken until a replacement is prescribed.
Patients should check the label of their prescription to determine if their medication is affected by the recall. If no information is available, they should contact their pharmacist.
Patients taking medication affected by the recall should follow the recall instructions provided by the specific company.
The Weinberg Group can help you avoid a recall and confirm that your product and procedures meet all of the Agency’s standards. Contact us today to learn more about our services and how we can help you with any and all of your quality and compliance related needs.
Final Guidance: Over-the-Counter Pediatric Oral Liquid Drug Products Containing Acetaminophen
After ongoing concern regarding potential overdose in OTC pediatric oral liquid drug products containing acetaminophen, FDA announced the availability of a final guidance earlier this week. Published...
FDA Warns of Serious Bleeding Risk Associated with Use of OTC Antacid Products Containing Aspirin
On Monday, June 6th the FDA issued a Drug Safety Communication, warning consumers about the increased risk of serious bleeding associated with the use of over-the-counter (OTC) antacid products that...